ExicureXCUR
$1.1+1.9%11월 13일 종가 기준
시가총액 $0.0B
3달 전보다 -36.5%
최고 $1.93최저 $0.89
지켜보기 의견AI 점수 50 / 100
신약 연구를 중단하고 파트너십과 인수합병 등 전략적 대안을 모색 중인 기업이에요.
Historically, the company was an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, they announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that they were exploring strategic alternatives to maximize stockholder value. Currently, they are exploring growth through acquisitions and transactions with potential partners and seeking additional financing.
최근 이벤트
- 기술 수출11월 10일오를 것 같아요
GPCRT가 회사의 GPC-100 자산을 65억 원(약 480만 달러)에 인수해요.